Haematologica (Jul 2020)

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study

  • Hanny Al-Samkari,
  • Raj S. Kasthuri,
  • Joseph G. Parambil,
  • Hasan A. Albitar,
  • Yahya A. Almodallal,
  • Carolina Vázquez,
  • Marcelo M. Serra,
  • Sophie Dupuis-Girod,
  • Craig B. Wilsen,
  • Justin P. McWilliams,
  • Evan H. Fountain,
  • James R. Gossage,
  • Clifford R. Weiss,
  • Muhammad A. Latif,
  • Assaf Issachar,
  • Meir Mei-Zahav,
  • Mary E. Meek,
  • Miles Conrad,
  • Josanna Rodriguez-Lopez,
  • David J. Kuter,
  • Vivek N. Iyer

DOI
https://doi.org/10.3324/haematol.2020.261859
Journal volume & issue
Vol. 106, no. 8

Abstract

Read online

Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) is a rare multisystem vascular disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Bevacizumab, an anti-vascular endothelial growth factor antibody, may be effective to treat bleeding in HHT. This international, multicenter, retrospective study evaluated the use of systemic bevacizumab to treat HHT-associated bleeding and anemia at 12 HHT treatment centers. Hemoglobin, epistaxis severity score, red cell units transfused, and intravenous iron infusions before and after treatment were evaluated using paired means testing and mixed-effects linear models. 238 HHT patients received bevacizumab for a median of 12 (range, 1-96) months. Compared with pretreatment, bevacizumab increased mean hemoglobin by 3.2 g/dL (95% CI, 2.9-3.5 g/dL) [mean hemoglobin 8.6 (8.5, 8.8) g/dL versus 11.8 (11.5, 12.1) g/dL, p